Search

Displaying results 3171 - 3180 of 10000 in total
  1. Drug

    Guanadrel

    go.drugbank.com/drugs/DB00226
    Approved

    Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.

  2. Drug

    Procarbazine

    go.drugbank.com/drugs/DB01168
    ApprovedInvestigational

    An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

    Synonyms: N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine, N-Isopropyl-α-(2-methylhydrazino)-p-toluamide
  3. Drug

    Anileridine

    go.drugbank.com/drugs/DB00913
    ApprovedIllicitWithdrawn

    Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effects are also caused by actions in the CNS.

    Synonyms: N-β-(p-aminophenyl)ethylnormeperidine, N-(β-(p-aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine
  4. Drug

    Umeclidinium

    go.drugbank.com/drugs/DB09076
    ApprovedInvestigational

    ANORO ELLIPTA was approved in December 2013 while TRELEGY ELLIPTA was approved in September 2017.[L46881,L46886] … [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.

  5. Drug

    Iroxanadine

    go.drugbank.com/drugs/DB05444
    Experimental

    It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). … EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease).

  6. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    Telisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting … [L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options.

  7. Drug

    AVI-4065

    go.drugbank.com/drugs/DB05620
    Investigational

    After phase II trials it was cancelled due to lack of potency. [L2917] … AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc.

  8. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with … [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia).

  9. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  10. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    On October 2021, Incyte Biosciences withdrew its application for a marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. … [L45603,L45613] The use of retifanlimab in combination with other oncology drugs for the treatment of metastatic gastroesophageal adenocarcinoma has also been evaluated.[A258383,A258388]